Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)
This study has been completed.
Information provided by (Responsible Party):
First received: September 17, 2009
Last updated: January 16, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2010|
|Primary Completion Date:||November 2009 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||December 10, 2010|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M, Schwarz TF, Watanveerade V, Wenzel JJ, Zalcman G, Bambure V, Li P, Caplanusi A, Madan A, Gillard P, Vaughn DW. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infect Dis. 2013 Sep 16;13:435. doi: 10.1186/1471-2334-13-435.